期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 121, 期 6, 页码 2149-2152出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI58025
关键词
-
资金
- NIDDK NIH HHS [R01 DK041274, 5R01DK067286, 2R01DK041274, R01 DK067286] Funding Source: Medline
Preclinical studies with probiotics continue to unravel mechanisms of cytoprotection and suggest that approaches utilizing microbial products as therapeutics in acute and chronic gastrointestinal disorders could be effective. However, clinical trials using these bacteria have thus far been inconsistent. In this issue of the JCI, Yan et al. describe a novel mechanism of cytoprotection by p40, a soluble product of Lactobacillus rhamnosus GG, mediated via EGER. The efficacy of p40 in three models of chemically induced colitis indicates tremendous therapeutic potential, though this finding will need to be verified in human patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据